抗精神病藥物市場規模、佔有率和成長分析（按治療層級、疾病、藥物、分銷管道和地區）- 2025-2032 年產業預測

2023 年抗精神病藥物市場規模價值 172.7 億美元，預計將從 2024 年的 182.7 億美元成長到 2032 年的 286.9 億美元，預測期內（2025-2032 年）的複合年成長率為 5.8%。

全球抗精神病藥物市場正在經歷強勁成長，這得益於人們對精神健康問題的認知不斷提高，以及政府和醫療機構為促進早期診斷和治療而做出的共同努力。思覺失調症和躁鬱症等精神疾病的增加推動了對第一代和第二代抗精神病藥物的需求。長效注射劑（LAI）和基於藥物基因組學的個人化治療等創新正在提高患者的依從性和治療效果。隨著提供即時洞察的數位療法的興起，市場也正在經歷向非典型抗精神病藥物的轉變。最近的收購和 FDA核准，例如強生公司以 150 億美元收購 Intra-Cellular Therapies，凸顯了旨在推進精神病護理和滿足對更安全、更有效治療的日益成長的需求的戰略投資。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

抗精神病藥物市場規模（依治療層級和複合年成長率） (2025-2032)

• 市場概況
• 第一代
• 第二代
• 第三代

抗精神病藥物市場規模（按疾病和複合年成長率） (2025-2032)

• 市場概況
• 思覺失調症
• 躁鬱症
• 單相憂鬱症
• 失智
• 其他疾病

抗精神病藥物市場規模（按藥物類型和複合年成長率） (2025-2032)

• 市場概況
• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• 帕利哌酮棕櫚酸酯
• 其他

抗精神病藥物市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 藥局和藥房
• 網路藥局

抗精神病藥物市場規模（按地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Johnson & Johnson（USA）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK）
• GlaxoSmithKline plc（UK）
• AbbVie Inc.（USA）
• Bristol-Myers Squibb（USA）
• H. Lundbeck A/S（Denmark）
• Sumitomo Pharma Co., Ltd.（Japan）
• Alkermes plc（Ireland）
• Dr. Reddy's Laboratories（India）
• Amgen Inc.（USA）
• Sanofi SA（France）
• Merck & Co., Inc.（USA）
• Novartis International AG（Switzerland）
• Roche Holding AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Sun Pharmaceutical Industries Ltd.（India）

結論和建議

Antipsychotic Drugs Market size was valued at USD 17.27 billion in 2023 and is poised to grow from USD 18.27 billion in 2024 to USD 28.69 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The global antipsychotic drugs market is witnessing robust growth, fueled by increased awareness of mental health issues and concerted efforts from governments and health organizations to promote early diagnosis and treatment. The rise in mental health disorders, such as schizophrenia and bipolar disorder, is driving demand for both first- and second-generation antipsychotic medications. Innovations in long-acting injectables (LAIs) and tailored therapies through pharmacogenomics are enhancing patient adherence and treatment outcomes. The market is also experiencing a shift towards atypical antipsychotics, coupled with the rise of digital therapeutics that provide real-time insights. Recent acquisitions and FDA approvals, such as Johnson & Johnson's $15 billion acquisition of Intra-Cellular Therapies, highlight strategic investments aimed at advancing psychiatric care and accommodating the growing demand for safer, effective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antipsychotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antipsychotic Drugs Market Segments Analysis

Global Antipsychotic Drugs Market is segmented by Therapeutic Class, Disease, Drug, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Drug, the market is segmented into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antipsychotic Drugs Market

A significant factor fueling the growth of the global antipsychotic drugs market is the escalating incidence of mental health disorders, such as schizophrenia and bipolar disorder. As awareness of these conditions rises, there is a growing demand for innovative treatment options as well as improved access to psychiatric care across the globe. This heightened understanding of mental health issues not only drives the development of new therapies but also emphasizes the necessity for comprehensive support systems for individuals affected by these disorders. Consequently, this trend is propelling the expansion of the antipsychotic drug market worldwide.

Restraints in the Antipsychotic Drugs Market

The global antipsychotic drugs market faces notable restraints, primarily due to regulatory challenges and protracted approval processes. These stringent regulations and extended clinical trial requirements hinder the timely introduction of new therapies, thereby impeding the speed at which groundbreaking medications can become available to patients. Such obstacles particularly affect market expansion in regions with rigid regulatory environments, further constraining the overall growth potential of the antipsychotic drug sector. Consequently, manufacturers and stakeholders must navigate these regulatory complexities, which can significantly delay the development and commercialization of innovative treatment options for mental health disorders.

Market Trends of the Antipsychotic Drugs Market

The antipsychotic drugs market is experiencing a notable trend towards the increasing demand for long-acting injectable antipsychotics, driven by the need for improved management of chronic psychiatric disorders such as schizophrenia. These innovative formulations allow for reduced dosing frequency, enhancing patient adherence and overall treatment effectiveness. Notably, pharmaceutical companies are investing in the development of new long-acting injectables that not only ensure sustained therapeutic efficacy but also prioritize patient convenience. This shift reflects a broader understanding of the complexities of mental health treatment, emphasizing the need for solutions that are both effective and user-friendly, positioning long-acting injectables as key players in the market's growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Antipsychotic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• First Generation
• Second Generation
• Third Generation

Global Antipsychotic Drugs Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Global Antipsychotic Drugs Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others

Global Antipsychotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Antipsychotic Drugs Market Size & CAGR (2025-2032)

• North America (Therapeutic Class, Disease, Drug, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Disease, Drug, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Disease, Drug, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Disease, Drug, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Disease, Drug, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations